These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1035530)

  • 1. [Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (4) Dyskinesia caused by levodopa].
    Mano T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):877-8. PubMed ID: 1035530
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Haas JA; Lakke JP
    Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y
    Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677
    [No Abstract]   [Full Text] [Related]  

  • 4. [Two cases of Parkinson's disease with diphasic dyskinesia, seen during levodopa treatment (author's transl)].
    Mano Y; Ando K; Muramoto O; Riku S
    Rinsho Shinkeigaku; 1982 Mar; 22(3):209-15. PubMed ID: 7105593
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term effects of home-made levodopa in 43 cases of paralysis agitans.
    Liu D; Jiang Y
    Chin Med J (Engl); 1979 Nov; 92(11):807-10. PubMed ID: 116825
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocular dyskinesias in patients with Parkinson's disease treated with levodopa.
    Shimizu N; Cohen B; Bala SP; Mendoza M; Yahr MD
    Ann Neurol; 1977 Feb; 1(2):167-71. PubMed ID: 889300
    [No Abstract]   [Full Text] [Related]  

  • 7. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects and side effects of levodopa in parkinsonism - results of a collaborative study. (3) Side effects of levodopa].
    Mizuno Y
    Rinsho Shinkeigaku; 1976 Dec; 16(12):874-6. PubMed ID: 1035529
    [No Abstract]   [Full Text] [Related]  

  • 9. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR; Obeso JA; Martínez-Lage JM
    Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dyskinesias induced by L-DOPA in Parkinson patients].
    García de Yébenes J; Muradas V; Bazán E; Reiriz J; Mena MA
    Arch Neurobiol (Madr); 1985; 48(4):197-209. PubMed ID: 4074075
    [No Abstract]   [Full Text] [Related]  

  • 11. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
    Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
    Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
    Nutt JG; Carter JH; Woodward W; Hammerstad JP; Gancher ST
    Mov Disord; 1993 Apr; 8(2):139-43. PubMed ID: 8474479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 17. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
    Strong JA; Dalvi A; Revilla FJ; Sahay A; Samaha FJ; Welge JA; Gong J; Gartner M; Yue X; Yu L
    Mov Disord; 2006 May; 21(5):654-9. PubMed ID: 16435402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects and side effects of levodopa in parkinsonism-results of a collaborative study. (1) Therapeutic responses in relation to the etiology and clinical types].
    Ito K
    Rinsho Shinkeigaku; 1976 Dec; 16(12):869-70. PubMed ID: 1035527
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anticholinergics and levodopa in Parkinson's disease: an unnecessary combination in patients treated for the 1st time].
    Giménez-Roldán S; Mateo D; Gil Núñez A
    Rev Clin Esp; 1980 Dec; 159(6):403-7. PubMed ID: 7221107
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement of L-dopa induced dyskinesia and of on-off phenomenon by bromocriptine.
    Ludin HP
    Acta Neurol Belg; 1980; 80(1):5-9. PubMed ID: 7361542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.